Drugs · acquisition-cost intelligence
AFREZZA
INSULIN HUMAN· ingredient insulin, regular, humanInsulins and analogues for inhalation· INSULIN HUMAN 12 [arb'U]/1; INSULIN HUMAN 4 [arb'U]/1; INSULIN HUMAN 8 [arb'U]/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$15.65
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other insulin, regular, human products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| Humulin R | $4.27 | −$11.39 |
| Novolin R | $5.22 | −$10.43 |
| Humulin R U-500 | $91.64 | +$75.99 |
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.